Top

Published in:

01-07-2016 | Original Article

Alpinetin targets glioma stem cells by suppressing Notch pathway

Authors: Jianpeng Wang, Zhiyong Yan, Xia Liu, Shusheng Che, Chao Wang, Weicheng Yao

Published in: Tumor Biology | Issue 7/2016

Abstract

Glioma is among the most common human malignancies with poor prognosis. Glioma stem cells (GSCs) are the culprit of glioma, suggesting that GSCs are potential therapeutic targets. Notch signaling pathway plays a pivotal role for the function of GSCs, implying that suppression of Notch pathway may be an effective strategy for GSC-targeting therapy. In this study, we found that alpinetin, a natural compound, can suppress the proliferation and invasiveness of GSCs and induce apoptosis in GSCs. Immunoblot analysis and luciferase assay revealed that Notch signaling was suppressed by alpinetin. Furthermore, restoration of Notch signaling activity rescued the effect of alpinetin on GSC’s function. The anti-tumor activity of alpinetin was further confirmed in an animal model. Collectively, targeting of GSC by alpinetin is an effective strategy for glioma therapy.

Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011;13(3):353–61. doi:10.1093/neuonc/noq203.CrossRefPubMedPubMedCentral

Jackson M, Hassiotou F, Nowak A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis. 2015;36(2):177–85. doi:10.1093/carcin/bgu243.CrossRefPubMed

Nakano I. Stem cell signature in glioblastoma: therapeutic development for a moving target. J Neurosurg. 2015;122(2):324–30. doi:10.3171/2014.9.JNS132253.CrossRefPubMed

Teodorczyk M, Schmidt MH. Notching on cancer's door: Notch signaling in brain tumors. Frontiers in oncology. 2014;4:341. doi:10.3389/fonc.2014.00341.PubMed

Colombo M, Galletti S, Garavelli S, Platonova N, Paoli A, Basile A, et al. Notch signaling deregulation in multiple myeloma: a rational molecular target. Oncotarget. 2015;6(29):26826–40. doi:10.18632/oncotarget.5025.CrossRefPubMedPubMedCentral

Yadav VR, Prasad S, Sung B, Aggarwal BB. The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol. 2011;11(3):295–309. doi:10.1016/j.intimp.2010.12.006.CrossRefPubMed

Yadav VR, Prasad S, Aggarwal BB. Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins. Br J Pharmacol. 2012;165(3):741–53. doi:10.1111/j.1476-5381.2011.01603.x.CrossRefPubMedPubMedCentral

Qin Y, Sun CY, Lu FR, Shu XR, Yang D, Chen L, et al. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-kappaB pathway in vitro. Leuk Res. 2012;36(4):514–20. doi:10.1016/j.leukres.2011.11.014.CrossRefPubMed

Park MK, Jo SH, Lee HJ, Kang JH, Kim YR, Kim HJ, et al. Novel suppressive effects of cardamonin on the activity and expression of transglutaminase-2 lead to blocking the migration and invasion of cancer cells. Life Sci. 2013;92(2):154–60. doi:10.1016/j.lfs.2012.11.009.CrossRefPubMed

10.

Kim EJ, Kim HJ, Park MK, Kang GJ, Byun HJ, Lee H, et al. Cardamonin suppresses TGF-beta1-Induced epithelial mesenchymal transition via restoring protein phosphatase 2A expression. Biomol Ther. 2015;23(2):141–8. doi:10.4062/biomolther.2014.117.CrossRef

11.

Tang Y, Fang Q, Shi D, Niu P, Chen Y, Deng J. mTOR inhibition of cardamonin on antiproliferation of A549 cells is involved in a FKBP12 independent fashion. Life Sci. 2014;99(1–2):44–51. doi:10.1016/j.lfs.2014.01.066.CrossRefPubMed

12.

Park S, Gwak J, Han SJ, Oh S. Cardamonin suppresses the proliferation of colon cancer cells by promoting beta-catenin degradation. Biol Pharm Bull. 2013;36(6):1040–4.CrossRefPubMed

13.

Wu N, Xiao L, Zhao X, Zhao J, Wang J, Wang F, et al. miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2. FEBS Lett. 2012;586(21):3831–9. doi:10.1016/j.febslet.2012.08.023.CrossRefPubMed

14.

Yan Z, Wang J, Wang C, Jiao Y, Qi W, Che S. miR-96/HBP1/Wnt/beta-catenin regulatory circuitry promotes glioma growth. FEBS Lett. 2014;588(17):3038–46. doi:10.1016/j.febslet.2014.06.017.CrossRefPubMed

15.

Kaushik G, Venugopal A, Ramamoorthy P, Standing D, Subramaniam D, Umar S, et al. Honokiol inhibits melanoma stem cells by targeting notch signaling. Mol Carcinog. 2014. doi:10.1002/mc.22242.PubMedPubMedCentral

16.

Lu Q, Tong B, Luo Y, Sha L, Chou G, Wang Z, et al. Norisoboldine suppresses VEGF-induced endothelial cell migration via the cAMP-PKA-NF-kappaB/Notch1 pathway. PLoS One. 2013;8(12):e81220. doi:10.1371/journal.pone.0081220.CrossRefPubMedPubMedCentral

17.

Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther. 2010;9(1):202–10. doi:10.1158/1535-7163.MCT-09-0771.CrossRefPubMedPubMedCentral

Title: Alpinetin targets glioma stem cells by suppressing Notch pathway
Authors: Jianpeng Wang
Zhiyong Yan
Xia Liu
Shusheng Che
Chao Wang
Weicheng Yao
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4827-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

Down-regulation of miR-320 associated with cancer progression and cell apoptosis via targeting Mcl-1 in cervical cancer

Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

A novel variable exonic region and differential expression of LINC00663 non-coding RNA in various cancer cell lines and normal human tissue samples

Increased expression of SOX4 is associated with colorectal cancer progression

The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines

Protein arginine methyltransferase 1 interacts with Gli1 and regulates its transcriptional activity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer